Our research indicated that by detecting the levels of ATF4, GPX4, GSS, KEAP1, and ATG3 in the peripheral blood of patients with ovarian cancer, their progression and prognosis could be rapidly, accurately, and effectively predicted, and their sensitivity to adjuvant therapy with ferroptosis-related drugs could be predicted. The gene discussed is KEAP1; the disease is ovarian carcinoma.